Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.78 |
| ▸ | MAOB | P27338 | 2/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.62 |
| ▸ | MGAM | O43451 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demethylmedicarpin SCHEMBL31663447 | 1.00 | MAOA (0.78) | MAOAMAOBCYP3A4PTPN1MGAM | |
| Demethylmedicarpin SCHEMBL29843376 | 1.00 | MAOA (0.78) | MAOAMAOBCYP3A4PTPN1MGAM | |
| SCHEMBL232991 | 0.92 | CYP3A4 (0.68) | MAOAMAOBCYP3A4PTPN1MGAM | |
| SCHEMBL19999737 | 0.91 | MAOA (0.67) | MAOAMAOBCYP3A4PTPN1MGAM | |
| Maackiain SCHEMBL28064249 | 0.88 | MAOA (1.00) | MAOAMAOBCYP3A4PTPN1MGAM | |
| Maackiain SCHEMBL29670858 | 0.88 | MAOA (1.00) | MAOAMAOBCYP3A4PTPN1MGAM | |
| Maackiain SCHEMBL12810278 | 0.88 | MAOA (1.00) | MAOAMAOBCYP3A4PTPN1MGAM | |
| SCHEMBL19999732 | 0.88 | MAPT (0.70) | MAOAMAOBCYP3A4PTPN1MGAM | |
| SCHEMBL72476 | 0.88 | MAPT (0.70) | MAOAMAOBCYP3A4PTPN1MGAM | |
| SCHEMBL31039664 | 0.88 | MAPT (0.70) | MAOAMAOBCYP3A4PTPN1MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114216983-A | Method for detecting residual quantity of medocard in animal food by liquid chromatography-tandem mass spectrometry | 广州广电计量检测股份有限公司 | 2022-03-22 | — | — | CN | claimed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230234920-A1 | Azirine Containing Compounds as Anti-Angiogenesis Agents and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-07-27 | — | — | US | disclosed |
| EP-4161493-A1 | AZIRINE CONTAINING COMPOUNDS AS ANTI-ANGIOGENESIS AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2023-04-12 | — | — | EP | disclosed |
| CN-114216983-A | Method for detecting residual quantity of medocard in animal food by liquid chromatography-tandem mass spectrometry | 广州广电计量检测股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114216983-A | Method for detecting residual quantity of medocard in animal food by liquid chromatography-tandem mass spectrometry | 广州广电计量检测股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-11235012-B2 | Combination and use of red propolis and red algae | BRETZ WALTER A (US) | 2022-02-01 | — | — | US | disclosed |
| US-20100242139-A1 | XENOHORMESIS BASED COMPOSITIONS AND METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-09-23 | — | — | US | disclosed |
| EP-1983848-A2 | XENOHORMESIS BASED COMPOSITIONS AND METHODS | The President and Fellows of Harvard College (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007084861-A2 | XENOHORMESIS BASED COMPOSITIONS AND METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234920-A1 | Azirine Containing Compounds as Anti-Angiogenesis Agents and a Process for the Preparation Thereof | FLT1, PGF, KDR | MAOA 957/4885MAOB 686/4885CYP3A4 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.